利用JC類病毒殼體攜帶自殺基因抑制轉移性去勢療法無效攝護腺癌細胞之生長

沈正煌1、周詠欽1、林勉君1、張德卿2、王梅林3

1嘉義基督教醫院泌尿外科; 2國立中正大學分子生物研究所; 3 中山醫學大學醫學系微免學科

Suppression of bone metastatic castration-resistant prostate cancer cell growth by a suicide gene delivered by JC polyomavirus-like particles

Cheng-Huang Shen1, Yeong-Chin Jou1, Mien-Chun Lin 1, Deching Chang2 and Meilin Wang3

1Department of Urology, Chiayi Christian Hospital, Chiayi, Taiwan; 2National Chung Cheng University, Chiayi, Taiwan; 3Department of Microbiology and Immunology, School of Medicine, Chung-Shan Medical University and Clinical Laboratory, Chung-Shan Medical University Hospital, Taichung, Taiwan

Purpose:

Our previous investigations demonstrated that the virus-like particles (VLPs) of JC polyomavirus (JCPyV) can deliver exogenous genes to prostate cancer cells for expression. JCPyV VLPs packaging pPSAtk (PSAtk-VLPs) possess the ability to transcriptionally target and selectively induce cytotoxicity only in prostate cancer cells. Thereafter, in the present study, we would further investigate whether PSAtk-VLPs inhibit the growth of metastasized prostate cancer cells.

Materials and Methods:

We established a CRPC cell line, 22Rv1-Luc, facilitating the use of an in vivo imaging system during the experiment. Furthermore, we established an animal model of bone-metastatic prostate cancer to compare PSAtk-VLPs with leuprorelin acetate and enzalutamide, hormonal agents commonly used in clinical settings, and investigated the effectiveness of PSAtk-VLPs in mCRPC.

Results:

In the present study, we observed that PSAtk-VLPs effectively inhibited the growth of prostate cancer cells that had metastasized to the bone in the metastatic animal model. In addition, PSAtk-VLPs showed a higher effectiveness than hormone therapy in this animal model study.

Conclusion:

These results suggest that PSAtk-VLPs may serve as a treatment option for mCRPC therapy in the future.